Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Wongchuensoontorn
Chanchai
C
Department of Oral and Maxillofacial Surgery, Srinakharinwirot University, Bangkok, Thailand.
Liebehenschel
Niels
N
Wagner
Kai
K
Fakler
Otto
O
Gutwald
Ralf
R
Schmelzeisen
Rainer
R
Sauerbier
Sebastian
S
D000284:Administration, Oral; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005593:Fracture Fixation, Internal; D005598:Fractures, Spontaneous / Q000209:etiology* / Q000601:surgery; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007275:Injections, Intravenous; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced*; D008337:Mandibular Fractures / Q000209:etiology* / Q000601:surgery; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D010166:Palliative Care; D014081:Tooth Extraction; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate